- Condition: Type 2 Diabetes Mellitus
Intervention: Behavioral: Lifestyle Counselling
Sponsors: University of Manitoba; University of Manitoba; Manitoba Institute of Child Health
Not yet recruiting - verified May 2012 - Conditions: Influenza, Human; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Infections; Respiratory Tract Diseases
Intervention: Biological: FVH1 - a DNA-based influenza vaccine
Sponsors: University of Manitoba; University of Manitoba; Inovio Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Muscle Development
Interventions: Dietary Supplement: Whey protein; Dietary Supplement: Chocolate milk; Dietary Supplement: Sugar
Sponsors: University of Manitoba; University of Manitoba
Recruiting - verified April 2012 - Condition: Sitosterolemia
Intervention: Drug: Ezetimibe
Sponsors: University of Manitoba; University of Manitoba
Recruiting - verified April 2012 - Condition: Total Parenteral Nutrition-induced Cholestasis
Interventions: Drug: Soybean oil based emulsion; Drug: Soybean oil based emulsion+Fish oil based emulsion
Sponsors: University Health Network, Toronto; University Health Network, Toronto; ASPEN Rhoads Research Foundation; Fresenius Kabi; University of Alberta; Foothills Medical Centre; St. Boniface General Hospital Research Centre; Hamilton Health Sciences Corporation; St. Paul's Hospital, Canada
Recruiting - verified February 2012 - Conditions: Hypercholesterolemia; Cardiovascular Disease; CRP
Intervention: Other: Standardized soy containing muffin
Sponsors: Guelph Food Research Centre; Guelph Food Research Centre; University of Guelph; Glycemic Index Laboratories, Inc; Canadian Centre for Agri-food Research in Health and Medicine
Not yet recruiting - verified March 2012 - Condition: Isolated Anterior Cruciate Ligament Rupture
Interventions: Other: Autograft STG harvest from ACL-deficient leg; Other: Autograft harvest contralateral to ACL-deficient leg
Sponsors: Panam Clinic; Panam Clinic
Active, not recruiting - verified February 2012 - Condition: Hypercholesterolemia
Interventions: Dietary Supplement: WD-PS intervention phase; Dietary Supplement: PS-Ester intervention phase; Dietary Supplement: placebo
Sponsors: University of Manitoba; University of Manitoba
Completed - verified December 2011 - Condition: Healthy Metabolism
Intervention: Drug: Amantadine
Sponsors: University of Manitoba; University of Manitoba; St. Boniface General Hospital Research Centre
Recruiting - verified November 2011 - Conditions: Lower Extremity Chronic Ulcers; Diabetes Mellitus
Interventions: Biological: Curexcell; Biological: Sham injection
Sponsors: Macrocure Ltd.; Macrocure Ltd.; Averion International Corporation
Recruiting - verified September 2011 - Condition: Above Optimal Blood Cholesterol
Interventions: Dietary Supplement: Control; Dietary Supplement: Low molecular weight/low viscosity beta-glucan; Dietary Supplement: Low molecular weight/low viscosity beta-glucan; Dietary Supplement: High molecular weight/high viscosity beta glucan
Sponsors: University of Manitoba; University of Manitoba; Agriculture and Agri-Food Canada
Active, not recruiting - verified August 2011 - Condition: Peripheral Artery Disease
Interventions: Other: control foods; Other: Mixed bean (higher amount); Other: Mixed beans (lower amount)
Sponsors: University of Manitoba; University of Manitoba; Pulse Canada
Recruiting - verified March 2012 - Condition: Influenza Vaccine
Interventions: Biological: Agriflu; Biological: Fluad; Biological: Intanza; Biological: Vaxigrip
Sponsors: University of British Columbia; University of British Columbia; PHAC/CIHR Influenza Research Network
Active, not recruiting - verified March 2012 - Conditions: SCID; ADA-SCID; XSCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified November 2011 - Condition: Healthy Volunteers
Interventions: Dietary Supplement: Krill oil; Dietary Supplement: Fish Oil
Sponsors: University of Manitoba; University of Manitoba; Enzymotec
Active, not recruiting - verified October 2011 - Condition: Peripheral Arterial Disease
Interventions: Other: traditional canola oil; Other: high oleic canola oil; Other: soybean oil; Other: high linoleic safflower oil; Other: coconut oil; Other: traditional canola oil; Other: safflower oil
Sponsors: University of Manitoba; University of Manitoba; St. Boniface General Hospital Research Centre
Recruiting - verified December 2011 - Conditions: Influenza, Human; Seasonal Influenza
Interventions: Biological: Quadrivalent seasonal influenza vaccine GSK2282512A; Biological: Fluarix®; Biological: Fluarix-YB; Biological: Quadrivalent seasonal influenza vaccine GSK2282512A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified August 2011 - Condition: Suicide
Intervention: Other: ASIST
Sponsors: University of Manitoba; University of Manitoba; American Foundation for Suicide Prevention
Active, not recruiting - verified August 2011 - Conditions: SCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis; ADA Deficiency; XSCID
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified November 2011 - Condition: Meningococcal Infections
Interventions: Biological: Meningococcal vaccine GSK 134612; Biological: Menactra®
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011 - Conditions: Haemophilus Influenzae Type b; Poliomyelitis; Hepatitis B; Serogroup C Meningococcal Diseases; Diphtheria; Pertussis; Pneumococcal Diseases; Tetanus
Interventions: Biological: GSK2202083A vaccine; Biological: Prevenar 13®; Biological: Infanrix hexa™; Biological: Menjugate®; Biological: Rotarix™
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011 - Condition: Sunburn
Intervention: Drug: Titanium dioxide
Sponsors: Loreal USA; Loreal USA
Completed - verified November 2009 - Condition: Influenza Infection
Interventions: Biological: GSK2340274A; Biological: GSK2340273A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012 - Conditions: Osteoarthritis; Traumatic Arthritis; Avascular Necrosis of the Femoral Condyle; Moderate Varus; Valgus; Flexion Deformities
Intervention: Device: NexGen LPS-Flex Mobile Bearing Knee
Sponsors: Zimmer, Inc.; Zimmer, Inc.
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Intervention: Other: buckwheat, rice crackers, glucose, sugar substitute
Sponsors: St. Boniface General Hospital Research Centre; St. Boniface General Hospital Research Centre; University of Manitoba
Completed - verified March 2012 - Conditions: Smoking Cessation; Insurance Coverage
Interventions: Other: Full Smoking Cessation Treatment Coverage (100%); Other: No Smoking Cessation Treatment Coverage (0%)
Sponsors: Pfizer; Pfizer
Completed - verified February 2012 - Condition: Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia.
Intervention: Biological: GSK580299, GSK Biological's HPV vaccine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012 - Condition: Influenza Virus
Interventions: Biological: GSK Biologicals' influenza vaccine GSK1557482A; Biological: Vaxigrip
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011 - Conditions: Cognition; Aging
Interventions: Drug: tamoxifen; Drug: raloxifene
Sponsors: Wake Forest University; Wake Forest University; National Institute on Aging (NIA)
Completed - verified May 2008 - Conditions: Acute Coronary Syndrome; Myocardial Infarction; Smoking
Interventions: Drug: Bupropion HCl ER; Drug: Placebo
Sponsors: McGill University; Mark Eisenberg; Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of Quebec
Completed - verified May 2008 - Condition: Vasomotor Symptoms
Interventions: Drug: desvenlafaxine succinate (DVS) SR; Drug: Placebo
Sponsors: Pfizer; Pfizer
Completed - verified July 2011 - Condition: Meningococcal Infections
Interventions: Biological: MenACWY-CRM; Biological: MenACWY-CRM; Biological: Licensed meningococcal ACWY vaccine
Sponsors: Novartis; Novartis Vaccines
Completed - verified December 2011 - Condition: Influenza
Interventions: Drug: oseltamivir; Drug: oseltamivir; Other: Alternative Control
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Contraception
Interventions: Drug: G04209F; Drug: G04209G
Sponsors: Bayer; Bayer
Active, not recruiting - verified April 2012 - Conditions: Obesity; Gestational Diabetes; Type 2 Diabetes
Intervention: Behavioral: Exercise and dietary education
Sponsors: University of Manitoba; University of Manitoba; The Lawson Foundation
Recruiting - verified August 2011 - Condition: Osteoarthritis, Knee
Intervention: Device: DePuy P.F.C.® Sigma Rotating Platform Knee
Sponsors: Queen's University; Queen's University; DePuy Orthopaedics
Active, not recruiting - verified April 2012 - Condition: Dyslipidaemias
Interventions: Drug: GW590735; Drug: fenofibrate
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012 - Conditions: Human Papillomavirus (HPV) Infection; Cervical Neoplasia
Interventions: Biological: Cervarix™; Biological: Havrix™-based investigational formulation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012 - Condition: Papillomavirus Infection
Intervention: Biological: HPV 16/18 VLP AS04
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011 - Condition: Breast Cancer
Intervention: Drug: exemestane
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; Grupo Espanol de Investigacion del Cancer de Mama; UNICANCER
Active, not recruiting - verified August 2011 - Condition: Leukemia
Interventions: Drug: asparaginase; Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: gemtuzumab ozogamicin; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Procedure: allogeneic bone marrow transplantation
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cyclosporine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Drug: imatinib mesylate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: vincristine sulfate; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation; Procedure: umbilical cord blood transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010


